Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Richter, Forest Report Positive Phase III Cariprazine Result

Don't Miss Out —
Follow us on:

Oct. 5 (Bloomberg) -- Gedeon Richter Nyrt., Hungary’s biggest drugmaker, and Forest Laboratories Inc. reported today “positive” results from a Phase III clinical trial of cariprazine, an antipsychotic agent.

Data showed that patients with acute manic episodes who were treated with cariprazine “experienced significant symptom improvement compared with placebo-treated patients,” the two companies said in a statement posted on the website of the Budapest Stock Exchange today.

To contact the reporter on this story: Andras Gergely in Budapest at agergely@bloomberg.net

To contact the editor responsible for this story: Gavin Serkin at gserkin@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.